| 1 |
33767436 | Generation of TRAIL-resistant cell line models reveals distinct adaptive mechanisms for acquired resistance and re-sensitization. | 2021 May |
1 |
| 2 |
32365976 | Chemotherapeutic Agents Sensitize Resistant Cancer Cells to the DR5-Specific Variant DR5-B more Efficiently than to TRAIL by Modulating the Surface Expression of Death and Decoy Receptors. | 2020 Apr 30 |
1 |
| 3 |
29916141 | Arginylated Calreticulin Increases Apoptotic Response Induced by Bortezomib in Glioma Cells. | 2019 Mar |
1 |
| 4 |
30713790 | Bortezomib sensitizes multiple myeloma to NK cells via ER-stress-induced suppression of HLA-E and upregulation of DR5. | 2019 |
1 |
| 5 |
29300929 | Downregulation of SKP2 in Papillary Thyroid Cancer Acts Synergistically With TRAIL on Inducing Apoptosis via ROS. | 2018 Apr 1 |
1 |
| 6 |
27978543 | The Proteasome Inhibitor Bortezomib Affects Chondrosarcoma Cells via the Mitochondria-Caspase Dependent Pathway and Enhances Death Receptor Expression and Autophagy. | 2016 |
1 |
| 7 |
26547077 | Mutations Enhancing Selectivity of Antitumor Cytokine TRAIL to DR5 Receptor Increase Its Cytotoxicity against Tumor Cells. | 2015 Aug |
1 |
| 8 |
25289891 | Bortezomib sensitizes primary meningioma cells to TRAIL-induced apoptosis by enhancing formation of the death-inducing signaling complex. | 2014 Nov |
1 |
| 9 |
25310712 | Combination of TRAIL with bortezomib shifted apoptotic signaling from DR4 to DR5 death receptor by selective internalization and degradation of DR4. | 2014 |
3 |
| 10 |
25341043 | Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism. | 2014 Oct 23 |
1 |
| 11 |
24377552 | Effects of arsenic trioxide alone and in combination with bortezomib in multiple myeloma RPMI 8266 cells. | 2013 |
1 |
| 12 |
22848091 | PKCĪ“ regulates death receptor 5 expression induced by PS-341 through ATF4-ATF3/CHOP axis in human lung cancer cells. | 2012 Oct |
6 |
| 13 |
20619923 | Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors. | 2011 Mar |
1 |
| 14 |
21393428 | Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A. | 2011 May |
2 |
| 15 |
19922463 | Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma. | 2010 Mar |
1 |
| 16 |
19039521 | Bortezomib treatment of ovarian cancer cells mediates endoplasmic reticulum stress, cell cycle arrest, and apoptosis. | 2009 Dec |
1 |
| 17 |
19174554 | Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib. | 2009 Feb |
1 |
| 18 |
18483298 | Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region. | 2008 May |
5 |
| 19 |
18544564 | Hypoxia-inducible factor-2alpha regulates the expression of TRAIL receptor DR5 in renal cancer cells. | 2008 Sep |
3 |
| 20 |
17326159 | TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. | 2007 Mar |
1 |
| 21 |
17510429 | The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. | 2007 May 15 |
10 |
| 22 |
17620439 | TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. | 2007 Jul |
1 |
| 23 |
17875785 | Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2. | 2007 Sep 15 |
1 |
| 24 |
16699949 | The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells. | 2006 Jul |
2 |
| 25 |
16082182 | Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation. | 2005 Jul |
1 |
| 26 |
16098063 | Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. | 2005 Aug |
1 |
| 27 |
12902978 | The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. | 2003 Aug 7 |
1 |